Answers are grounded in this paper and cite their sources.
ET measurements using OCT can detect an early subclinical response to secukinumab compared to clinical scoring and identify nonresponders as early as 4 weeks.
No takes yet. Share an insight, caveat, or question.
Felice et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: